KALV — Kalvista Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: KalVista Pharma to Present Phase 3 Sebetralstat Data
U.S. STOCKS ON THE MOVE-Super Micro, Albemarle
U.S. STOCKS ON THE MOVE-Ginkgo, Jfrog, Alvotech
U.S. STOCKS ON THE MOVE-EPAM, CBRE, Zebra Technologies
KalVista Pharma rebounds as stock offering prices at a premium
Brief: Kalvista Pharma Announces Pricing Of A $160.1 Mln Public Offering Of Common Stock And Pre-Funded Warrants
U.S. RESEARCH ROUNDUP-Bruker Corp, Cymabay Therapeutics, SSR Mining
U.S. STOCKS ON THE MOVE-JetBlue Airways, LPL Financial, Nvidia
U.S. STOCKS ON THE MOVE-Bicycle Therapeutics, Molson Coors, LianBio
KalVista Pharma rises as genetic disorder drug succeeds in late-stage study
KalVista meets main goals in late-stage trial for genetic disease (updated)
KalVista meets main goals in late-stage trial for skin condition treatment
Brief: KalVista Pharma Says Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy
Kalvista Pharmaceuticals Inc reports results for the quarter ended in October - Earnings Summary
Brief: Kalvista Pharmaceuticals Q2 Net Income USD -27.65 Million
Kalvista Pharmaceuticals Inc expected to post a loss of 79 cents a share - Earnings Preview
Kalvista Pharmaceuticals Inc reports results for the quarter ended in July - Earnings Summary
Kalvista Pharmaceuticals Inc expected to post a loss of 86 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Cava Group, Citizens Financial, Integral Ad Science Holding